Why did this ASX All Ords share plunge 18% today?

It's another day deep in the red for this healthcare company.

| More on:
ASX 200 investor looking frustrated at falling share price whilst sitting at desk

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX All Ords healthcare share Mayne Pharma Group Ltd (ASX: MYX) is down again on Friday as investors continue to digest the company's unaudited FY23 full-year results released yesterday.

The Mayne Pharma share price is currently $3.33, down 9.2%. In earlier trading, it fell to an intraday low of $3.01, down 18%.

Yesterday, the ASX All Ords share took a 23% dive after the financial figures were released.

This is adding up to a two-day tragedy for Mayne Pharma. At its intraday low today, the ASX All Ords share was 36% down on Wednesday's closing price.

Ouch.

FY23 was a year of transformation for Mayne Pharma. The company is seeking to narrow its focus within the healthcare sector to primarily women's health and dermatology.

Let's review the key points of the healthcare company's report.

Two-day tragedy for ASX All Ords share

Let's start with the good news.

Mayne Pharma said it achieved reported revenue of $183.6 million in FY23, up 17% on FY22. The reported gross profit was $83.5 million, also up 17% on FY22.

The company improved its net cash position in FY23. As of 30 June, it had $172.6 million net cash compared to net debt of $317 million at the end of FY22.

But the reported earnings before interest, taxes, depreciation, and amortisation (EBITDA) came in at a loss of $102 million for FY23. This compares to a positive EBITDA of $9 million in FY22.

Mayne Pharma reported a net loss after tax of $317.4 million, down 44% on FY22.

Shareholders will receive no final dividend.

Steps toward company transformation

Mayne Pharma is seeking to become a specialty pharmaceutical company with a leading position in women's health and dermatology.

To this end, in FY23, the company sold its Metrics Contract Services business for US$475 million and its US retail generics portfolio business for US$90 million.

Mayne Pharma spent US$140 million buying the exclusive US license to a portfolio of on-market women's health products (ANNOVERA, IMVEXXY and BIJUVA) and prenatal vitamins.

During the year, the company paid a fully franked special dividend of 2.72 cents per share and commenced a share buyback of up to 10% of issued capital.

A year of 'significant change': CEO

Mayne Pharma CEO Shawn Patrick O'Brien, who joined the company in October 2022, said:

Fiscal year 2023 has been one of significant change at Mayne Pharma.

With accelerating sales momentum and ongoing cost discipline, Mayne Pharma enters FY24 well positioned for sustainable long-term growth.

Mayne Pharma said it anticipated returning to positive EBITDA and cash generation in FY24.

Recent history of this ASX All Ords share

The Mayne Pharma share price is down 21% in the year to date. The ASX All Ords healthcare share has tumbled 41% over the past 12 months.

By comparison, the S&P/ASX 200 Health Care Index (ASX: XHJ) has fallen 1.4% over the same period.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Which ASX 200 healthcare share will pay the best dividend yield in 2025?

Earnings season is underway and dividend announcements are on investors' minds.

Read more »

A person is weighed down by a huge stack of coins, they have received a big dividend payout.
Dividend Investing

Looking to bag the record high ResMed dividend? You better hurry!

Unlike the majority of ASX 200 income stocks, ResMed pays dividends every quarter.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 reasons to buy CSL shares today

Two investment experts expect a big turnaround for CSL shares in 2025.

Read more »

Business people discussing project on digital tablet.
Healthcare Shares

Down 4%, is the ResMed share price in the buy zone?

Do analysts think investors should be buying the dip? Let's see what they are saying.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Guess which ASX 100 share is sinking 8% because of Trump's tariffs

Donald Trump has dealt this company a big blow. What's happening?

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Up 1,090% in a year, why is the Mesoblast share price leaping higher again on Friday?

Mesoblast shares have surged more than 1,000% over the last 12 months.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Earnings Results

ResMed shares rise on strong Q2 result

Let's see how this sleep treatment company performed during the second quarter.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

$1,000 invested in Mesoblast shares at the start of 2024 is now worth…

Did this biotech company deliver the goods for investors? Let's see what a $1,000 investment would be worth.

Read more »